OUR LATEST NEWS
March 24, 2023
ABL APPOINTS STEPHANIE COLLOUD AS GENERAL MANAGER AND CHIEF OPERATING OFFICER TO LEAD EUROPEAN ACTIVITIES
October 25, 2022
ABL AND RD-BIOTECH SIGN STRATEGIC PARTNERSHIP IN CELL AND GENE THERAPY GMP MANUFACTURING
October 18, 2022
ABL AND IMUGENE PARTNER TO ADVANCE ONCOLYTIC VIRUS CANDIDATE TOWARDS LATER PHASE CLINICAL TRIALS
July 11, 2022
ABL PARTNERS WITH KALIVIR IMMUNOTHERAPEUTICS TO ADVANCE DEVELOPMENT OF ONCOLYTIC VIRUSES
June 9, 2022
COAVE THERAPEUTICS AND ABL ENTER INTO STRATEGIC COLLABORATION
April 17, 2022